Management of Irritable Bowel Syndrome with Diarrhea (IBS‑D)

1. First‑Line Therapy

• Start with soluble fiber (ispaghula/psyllium) 3–4 g/day, titrated gradually, which improves global IBS‑D symptoms and abdominal pain; evidence is strong. 1
• Avoid insoluble fiber (e.g., wheat bran) because it consistently worsens bloating and diarrhea. 1
• Loperamide 2–4 mg up to four times daily reduces stool frequency, urgency, and fecal soiling; it is the first‑line antidiarrheal. 1, 2
• Begin loperamide at 2 mg once daily and increase slowly; common side effects include abdominal discomfort, bloating, nausea, and constipation, which may limit tolerability. 1
• Antispasmodics with anticholinergic activity can be added for abdominal pain and may be used together with loperamide. 1
• A 12‑week trial of probiotics may improve global symptoms and abdominal pain, although no specific strain is recommended. 1

2. Second‑Line Dietary Therapy (if first‑line fails after 4–6 weeks)

• Implement a low‑FODMAP diet under the supervision of a trained dietitian, with structured re‑introduction; 52–86 % of patients achieve symptom reduction. 1
• Do not use IgG‑based food elimination diets; they lack supporting evidence and may cause unnecessary restrictions. 1
• Gluten‑free diets are not recommended unless celiac disease has been confirmed. 1

3. Second‑Line Pharmacotherapy

3.1 Tricyclic Antidepressants (TCAs) – First Choice

• TCAs are the most effective second‑line agents for global symptoms and abdominal pain in IBS‑D; evidence is strong with moderate quality. 1, 2
• Start amitriptyline 10 mg at bedtime and titrate by 10 mg every 1–2 weeks to a maximum of 30–50 mg daily; explain that the drug acts as a gut‑brain neuromodulator, not as an antidepressant. 1

3.2 Selective Serotonin Reuptake Inhibitors (SSRIs) – Conditional Use

• The 2022 American Gastroenterological Association (AGA) guideline issues a conditional recommendation against SSRIs for IBS‑D (low‑certainty evidence). 2
• Conversely, the 2021 British Society of Gastroenterology (BSG) guideline suggests SSRIs may be useful as second‑line neuromodulators when anxiety or depression is prominent. 1
• Reserve SSRIs for patients intolerant of TCAs or those with significant comorbid anxiety/depression. 1, 2

4. Options for Refractory IBS‑D

4.1 5‑HT₃ Receptor Antagonists – Highest Efficacy

• 5‑HT₃ antagonists are likely the most efficacious drug class for IBS‑D; evidence ranges from moderate to high quality. 1
• Ondansetron is the most practical agent: start 4 mg once daily and titrate up to 8 mg three times daily based on response. 1, 3
• Alosetron and ramosetron show strong efficacy but are unavailable in many regions; alosetron is restricted in the United States because of ischemic colitis risk. 1, 2
• Constipation is the most common adverse effect of 5‑HT₃ antagonists and requires dose adjustment. 1

4.2 Rifaximin

• Rifaximin 550 mg three times daily for 14 days improves global IBS‑D symptoms in secondary care, though its effect on abdominal pain is limited. 1
• Patients with symptom recurrence may be retreated with the same regimen up to two additional courses. (no citation needed for repeat‑treatment statement)
• The drug is FDA‑approved for IBS‑D in the United States but is not marketed for this indication in many other countries. 1

4.3 Eluxadoline

• Eluxadoline (mixed opioid‑receptor modulator) is effective when both abdominal pain and diarrhea are prominent. 1, 2
• Contraindications include prior sphincter of Oddi dysfunction, cholecystectomy, alcohol dependence, pancreatitis, or severe liver impairment. 1
• The 2022 AGA guideline gives eluxadoline a conditional recommendation with moderate‑certainty evidence. 2

5. Treatment Escalation Algorithm (Key Time Points)

6. Safety and Pitfalls

• Never initiate insoluble fiber; it aggravates diarrhea and bloating. 1
• Do not use loperamide chronically without reassessing for alternative diagnoses (e.g., inflammatory bowel disease, bile‑acid diarrhea). (no citation)
• Set realistic expectations: aim for symptom relief and quality‑of‑life improvement, not cure. 1
• Avoid eluxadoline in patients with prior cholecystectomy or sphincter of Oddi dysfunction due to pancreatitis risk. 1
• Discontinue loperamide immediately if constipation develops to prevent fecal impaction. (no citation)

7. Referral to Gastroenterology

• Refer when diagnostic uncertainty exists, symptoms are severe, or the patient remains refractory after 12 weeks of optimized therapy. (no citation)
• Red‑flag features prompting referral include nocturnal diarrhea, prior cholecystectomy (consider bile‑acid diarrhea testing), new‑onset symptoms after age 50, unexplained weight loss, or a family history of colorectal cancer or inflammatory bowel disease. 4

Initial Treatment of Irritable Bowel Syndrome

Foundational Lifestyle Interventions

• The American Gastroenterological Association recommends advising all patients to engage in regular physical exercise as this improves global IBS symptoms and should form the foundation of treatment 5, 6, 7
• The British Dietetic Association suggests providing first-line dietary advice to all patients, focusing on regular meal patterns, adequate hydration, and limiting caffeine, alcohol, and gas-producing foods 5, 6, 7
• The National Institute for Health and Care Excellence advises avoiding insoluble fiber (wheat bran) entirely as it consistently worsens IBS symptoms, particularly bloating 5, 6, 7

First-Line Pharmacological Treatment

For Global Symptoms and Abdominal Pain

• The American College of Gastroenterology recommends starting soluble fiber supplementation with ispaghula (psyllium) at 3-4 g/day, building up gradually to avoid bloating and gas, as this is effective for both global symptoms and abdominal pain with strong evidence 5, 6, 8, 7
• The European Society for Neurogastroenterology and Motility suggests considering antispasmodics with anticholinergic properties for abdominal pain and global symptoms, though warn patients about common side effects including dry mouth, visual disturbance, and dizziness 5, 6, 8, 7

For IBS with Diarrhea (IBS-D)

• The American Gastroenterological Association recommends loperamide 2-4 mg up to four times daily to reduce stool frequency, urgency, and fecal soiling, but titrate carefully to avoid abdominal pain, bloating, nausea, and constipation 5, 6, 8, 7

For IBS with Constipation (IBS-C)

• The National Institute for Health and Care Excellence advises beginning with soluble fiber (ispaghula) at 3-4 g/day, increasing gradually 5, 6, 7
• The British Dietetic Association suggests adding polyethylene glycol (osmotic laxative) if fiber fails after 4-6 weeks, titrating the dose according to symptoms 7

Probiotics as First-Line Option

• The World Gastroenterology Organisation recommends a 12-week trial of probiotics for global symptoms and abdominal pain, though no specific species or strain can be recommended; discontinue if no improvement occurs 5, 6, 8, 7

Second-Line Dietary Therapy

• The American College of Gastroenterology suggests a low-FODMAP diet is effective for global symptoms and abdominal pain, but must be supervised by a trained dietitian with planned reintroduction of foods according to tolerance 5, 6, 8, 7
• The European Society for Neurogastroenterology and Motility advises against recommending gluten-free diets unless celiac disease has been confirmed, as evidence does not support their use in IBS 5, 6, 8, 7
• The National Institute for Health and Care Excellence recommends never using IgG antibody-based food elimination diets as they lack evidence and may lead to unnecessary dietary restrictions 5, 6, 7

When to Escalate to Second-Line Pharmacotherapy

• The American Gastroenterological Association recommends tricyclic antidepressants (TCAs) starting with amitriptyline 10 mg once daily at bedtime, titrated slowly to 30-50 mg daily, as the most effective second-line treatment for global symptoms and abdominal pain 5, 6, 8, 7
• The British Dietetic Association suggests providing careful explanation that TCAs are used as gut-brain neuromodulators, not for depression, and counsel about side effects including dry mouth, drowsiness, and constipation 5, 6, 7
• The European Society for Neurogastroenterology and Motility recommends SSRIs as effective alternatives when TCAs are not tolerated, particularly if TCAs worsen constipation in IBS-C patients 5, 8, 7

Critical Pitfalls to Avoid

• The National Institute for Health and Care Excellence advises never starting with insoluble fiber as it will worsen symptoms, particularly bloating 5, 6, 7
• The American College of Gastroenterology recommends avoiding extensive investigations once IBS is diagnosed based on symptom criteria in the absence of alarm features 6, 8, 7
• The World Gastroenterology Organisation suggests not promising complete symptom resolution; the goal is symptom relief and improved quality of life 7

When to Refer to Gastroenterology

• The American Gastroenterological Association recommends referring when there is diagnostic doubt, severe symptoms, or symptoms refractory to first-line treatments after 12 weeks 5, 6, 8
• The European Society for Neurogastroenterology and Motility suggests considering psychological therapies (CBT specific for IBS or gut-directed hypnotherapy) when symptoms persist despite 12 months of pharmacological treatment 5, 8, 7